Jafron Biomedical released its 2026 half-year report, with net profit attributable to the parent reaching 382 million yuan in the first half, down 1.99% year-on-year. The company's operating revenue for the same period was 1.032 billion yuan, down 9.0% year-on-year, and net profit attributable to the parent after deducting non-recurring items was 355 million yuan, down 4.71% year-on-year. In the second quarter, operating revenue was 472 million yuan and net profit attributable to the parent was 161 million yuan, both down 19.6% year-on-year. The company stated that by optimizing its organizational structure and strengthening expense control, the decline in net profit was smaller than the decline in revenue, achieving certain results in cost reduction and efficiency improvement, while overseas sales revenue increased by 20.37% year-on-year.
Jafron Biomedical Co LtdH1 net profit down 1.99% and revenue down 9.0% year-on-year, with Q2 declines of 19.6%.
